TYMP has been shown to increase in tumor samples of patients receiving anthracycline-and taxane-based preoperative chemotherapy for breast cancer and this observation provided the rationale for several studies which evaluated the addition of capecitabine to taxane-based therapy 22–24. This evidence concerns the gene TYMP and neoplasm.